Form 4: Anika Therapeutics EVP, CFO & COO Reports Routine RSU Vesting and Share Transactions

Stephen D. Griffin, Anika Therapeutics' EVP, CFO & COO, reported the vesting of 12,840 Restricted Stock Units and related share transactions, including tax withholding, on June 3, 2025.

Summary

• Stephen D. Griffin, Executive Vice President, Chief Financial Officer, and Chief Operating Officer of Anika Therapeutics, Inc. (ANIK), filed a Form 4 detailing changes in his beneficial ownership on June 3, 2025.
• He acquired 12,840 shares of common stock as a result of the first vesting installment of Restricted Stock Units (RSUs) that were originally granted on June 3, 2024.
• Concurrently, 3,769 shares of common stock were withheld by Anika Therapeutics to satisfy tax withholding obligations related to this RSU vesting, based on a closing price of $11.59 per share on June 3, 2025.
• Following these transactions, Mr. Griffin directly owns 9,871 shares of common stock.
• Additionally, he holds 25,680 Restricted Stock Units, which represent the contingent right to receive common stock and are scheduled to vest in two further equal annual installments beginning June 3, 2025.
• His beneficial ownership prior to the tax withholding, but after the RSU conversion, included 800 shares acquired on May 14, 2025, under the Anika Therapeutics, Inc. Employee Stock Purchase Plan.

Sentiment

Score: 6

Explanation: The document reports a routine executive compensation event (RSU vesting) and associated tax withholding, which is a neutral to slightly positive indicator of executive alignment and retention, but does not contain new operational or financial performance information.

Positives

• Vesting of 12,840 Restricted Stock Units (RSUs) for Stephen D. Griffin, EVP, CFO & COO, indicating the realization of long-term incentive compensation and aligning executive interests with shareholder value.
• Acquisition of 800 shares under the Anika Therapeutics, Inc. Employee Stock Purchase Plan on May 14, 2025, demonstrating continued participation in employee stock ownership.

Negatives

• 3,769 shares of common stock were withheld by the Issuer to cover tax withholding obligations arising from the RSU vesting, which is a standard and expected procedure for equity compensation and not indicative of negative company performance.

Future Outlook

The remaining 25,680 Restricted Stock Units (RSUs) held by Stephen D. Griffin are scheduled to vest in two additional equal annual installments following the initial vesting on June 3, 2025.

Industry Context

This Form 4 filing is a routine disclosure of an insider's equity transactions, specifically related to executive compensation. It does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders: This filing indicates the company's executive compensation structure, showing how key management is incentivized through equity. The vesting and retention of shares by a senior executive like the EVP, CFO & COO can be viewed positively as it aligns management's financial interests with long-term shareholder value.
• Employees: The document highlights the company's use of equity-based compensation plans, which can be a positive factor for employee retention and motivation, particularly for key personnel.

Next Steps

• Future annual vesting installments of the remaining 25,680 Restricted Stock Units (RSUs) held by Stephen D. Griffin.

Key Dates

Keywords

Anika Therapeutics, ANIK, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Executive Compensation, Stock Ownership, Employee Stock Purchase Plan